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ABSTRACT
Numerous mammalian proto-oncogene and other
growth-regulatory transcripts are upregulated in ma-
lignancy due to abnormal mRNA stabilization. In hep-
atoma cells expressing a hepatitis C virus (HCV)
subgenomic replicon, we found that the viral non-
structural protein 5A (NS5A), a protein known to bind
to viral RNA, also bound specifically to human cellu-
lar transcripts that encode regulators of cell growth
and apoptosis, and this binding correlated with tran-
script stabilization. An important subset of human
NS5A-target transcripts contained GU-rich elements,
sequences known to destabilize mRNA. We found
that NS5A bound to GU-rich elements in vitro and in
cells. Mutation of the NS5A zinc finger abrogated its
GU-rich element-binding and mRNA stabilizing activ-
ities. Overall, we identified a molecular mechanism
whereby HCV manipulates host gene expression by
stabilizing host transcripts in a manner that would
promote growth and prevent death of virus-infected
cells, allowing the virus to establish chronic infec-
tion and lead to the development of hepatocellular
carcinoma.
INTRODUCTION
For viruses to survive and replicate, they often control the
host cellular environment by manipulating host gene ex-
pression. It is becoming increasingly clear that viral manip-
ulation of host posttranscriptional regulatory mechanisms
plays critical roles in viral pathogenesis. For example, Ka-
posi’s sarcoma herpes virus globally down-regulates expres-
sion of host cellular transcripts by expressing the shut-off al-
kaline exonuclease (SOX), which mediates transcript degra-
dation (1). Herpes simplex virus selectively degrades cer-
tain host transcripts through a viral endonuclease (2) but
stabilizes and up-regulates a specific subset of host cellular
transcripts through the viral ICP27 protein (3). By utilizing
posttranscriptional mechanisms, viruses are able to selec-
tively manipulate the expression of host transcripts to create
a cellular environment that inhibits antiviral host defense
mechanisms and allows the establishment of viral infection.
Hepatitis C virus (HCV), which belongs to the family Fla-
viviridae family of viruses (4), is a RNA virus with a 9.6
kb RNA genome of positive polarity that encodes struc-
tural and nonstructural proteins required for HCV repli-
cation (5). HCV infects approximately 184 million people
worldwide (6) and causes hepatitis, liver cirrhosis and hep-
atocellular carcinoma (7). The mechanisms leading to liver
cirrhosis and cancer in the HCV-infected individual are not
understood. In the current era, cure of HCV infection with
new antivirals is possible, but even patients with virological
cure have an increased risk of developing hepatocellular car-
cinoma (8,9). Therefore, understanding the molecular pro-
gression of HCV infection to hepatocellular carcinoma is a
priority.
Due to its small genome, HCV must use the host protein
synthesis machinery to produce viral proteins required for
viral replication. One of these viral proteins, non-structural
protein 5A (NS5A), is multifunctional and influences many
viral and cellular processes. The entire protein-protein in-
teraction network of the HCV proteome was mapped by
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high throughput yeast two hybrid screening, and NS5A 
was found to interact with proteins functioning in focal 
adhesions, gap-junctions and host cellular signaling path-
ways (10). NS5A also influences c ell c ycle c ontrol b y in-
teracting with p53 and modulation of p21 (11–14). During 
viral genome replication, NS5A interacts with the RNA-
dependent RNA-polymerase NS5B (15,16), an interaction 
that is essential to maintain the HCV subgenomic replicon 
in Huh 7 cells (15,17). NS5A also binds to G- and U-rich 
sequences in HCV genomic RNA (18). The amino terminal 
domain 1 and the adjacent unstructured region of NS5A 
interacts with HCV genomic RNA (16) and modulates its 
template selection (19). Crystal structures of domain 1 show 
a RNA-binding zinc finger which c oordinates a  Z n2+ ion 
(20,21). We hypothesized that NS5A functions to regulate 
the expression of host genes at posttranscriptional levels 
through its ability to bind to G and U rich RNA sequences. 
We previously described a GU-rich element (GRE) that 
is enriched in the 3′ untranslated region (UTR) of rapidly 
degraded cellular transcripts expressed in primary human 
T cells (22). GRE-containing transcripts encode numer-
ous proto-oncogene proteins and other proteins involved 
in cell growth regulation or apoptosis (23). Insertion of the 
GREs from JUN, JUNB or TNFRSF1B mRNAs into the 
3′ UTR of a beta-globin reporter transcript conferred in-
stability onto the otherwise stable beta-globin transcript. 
Further investigation showed that the CUGBP1 and ETR-
3––Like Factor 1 (CELF1) protein functions as a GRE-
binding protein and mediates the decay of GRE-containing 
transcripts (22), perhaps by recruiting other enzymatically 
active proteins to the transcript. The Xenopus homologue 
of CELF1, EDEN-BP, also binds to GREs and is involved 
in deadenylation of mRNA during oocyte maturation (24). 
In mammalian cell extracts, CELF1 interacts with poly A ri-
bonuclease and mediates transcript deadenylation (25). The 
GRE and CELF1 define a  posttranscriptional mechanism 
for coordinately regulating the expression of multiple tran-
scripts involved in cellular growth and apoptosis, and we hy-
pothesized that HCV manipulates this mechanism through 
its NS5A protein to create a cellular environment that pre-
vents cell death and promotes growth of virus-infected cells. 
In this report, we demonstrate that the HCV NS5A pro-
tein does indeed bind to host transcripts, including a large 
set of GRE-containing transcripts and mediates their stabi-
lization. Expression of a subgenomic HCV replicon in the 
Huh 7.5 human hepatoma cell line led to binding by NS5A 
to host GRE-containing transcripts, which correlated with 
the stabilization of these transcripts. NS5A expressed ex-
ogenously in HeLa cells bound to reporter transcripts in 
a GRE-dependent manner, and this binding led to tran-
script stabilization, demonstrating that NS5A has RNA-
stabilizing activity in cells. A purified recombinant NS5A 
polypeptide bound to GRE sequences in a zinc finger-
dependent manner. Mutation of the zinc finger abolished 
the RNA-binding and the mRNA stabilizing activity of 
NS5A. Together, these data suggest that HCV manipulates 
host cellular mRNA decay through NS5A-mediated stabi-
lization of host transcripts. Because GRE-containing NS5A 
target transcripts encode proto-oncogenes and other impor-
tant regulators of cell growth and apoptosis, HCV-induced 
stabilization of these transcripts would prevent cell death
and promote growth of virus-infected cells, allowing the
virus to establish a chronic infection and thereby promote
the development of hepatocellular carcinoma.
MATERIALS AND METHODS
Cell culture
The human hepatoma cell line Huh 7.5 (Huh) is a deriva-
tive of the Huh7 human hepatoma cell line attenuated
in the RIG-I/interferon regulatory factor 3 (IRF-3) path-
way (26). The Huh 7.5 SI cell line (Huh-HCV) stably
expresses the HCV-Con1 replicon with an adaptive mu-
tation in NS5A-coding sequence producing the S.2204.I
variant (18). This cell line was generated by transfect-
ing 1.6 × 106 Huh 7.5 cells with 2 g of in vitro tran-
scribed replicon RNA using TransMessenger transfection
system (Qiagen). After transfection, 1 × 105 cells were
seeded in 100-mm diameter dishes and 12–14 h later the
cells were placed under G418 selection (500 g/mL) for 3
weeks and colonies were further expanded. Huh and Huh-
HCV cells were propagated in Dulbecco’s modified eagle’s
medium (DMEM, Gibco) supplemented with 10% FBS
(Atlanta biologicals), 0.1 mM nonessential amino acids
(Gibco), 1% L-Glutamine (Gibco) and 100 units/ml of
penicillin/streptomycin (Gibco). For Huh-HCV cells, 500
g/ml of G418 (Calbiochem) was added to the medium.
HeLa Tet-off cells (Clontech) were cultured in minimal es-
sential medium alpha (Gibco) containing 10% tetracycline-
free FBS (Clontech), 1% L-glutamine (Gibco) and 100
units/ml of penicillin/streptomycin (Gibco).
Plasmids
The pTracerC green fluorescence protein (GFP) expres-
sion plasmid and the pcDNA3 plasmid were purchased
from Invitrogen. The tet-responsive beta-globin expres-
sion plasmid pTetBBB (BBB) (27) was a gift from Dr
Ann-Bin Shyu (University of Texas-Houston). We pre-
viously described insertion of the JUNB GRE, mutated
JUNB GRE or IL2 ARE sequences into the 3′ UTR
of the beta-globin sequence of the BBB plasmid to cre-
ate the BBB-GRE, BBB-mGRE and BBB-ARE plas-
mids, respectively (22,28). To generate pCDNA3.1–5A
and pCDNA3.1-del32–5a NS5A was PCR-amplified from
the plasmid pHCVbart.rep1b/Ava-II (29), a gift from
Dr Charles Rice (Rockefeller University) with primers
FW-5a, 5′-GCGTCTAGAATGGGCTCCGGCTCGTGG
CTA-3′ or FW-del32-5a 5′-GCGTCTAGAATGGGCGG
AGTCCCCTTCTTC-3′ and RV-5a, 5′-GCGCAAGCTTC
TATTAGCAGCAGACGACATC-3′ and inserted into the
XbaI and HindIII sites of pCDNA3.1 (Invitrogen). The
NS5A expression plasmid pCDNA3.1–5A was used to ex-
press NS5A in HeLa cells and pCDNA3.1-del32–5a was
used to express the NS5A N mutation. The QuikChange
Site-Directed Mutagenesis Kit (Stratagene) was used to
introduce four cysteine to serine mutations (C39S, C57S,
C59S, and C80S) into these plasmids to create pCDNA3.1–
5A-4C-4S and pCDNA3.1-del32–5a-4C-4S which express
the NS5A 4C-4S and NS5A N-4C-4S mutations, respec-
tively.
Plasmids for expression of recombinant NS5A polypep-
tides in Escherichia coli were created by cloning PCR am-
plified sequences from NS5A into the pSUMO plasmid
(LifeSensors Inc). The following PCR primers were used
to amplify the NS5A-domain 1+ coding sequence from
the plasmid pHCVbart.rep1b/Ava-II (29): 5′-GCG GGT
CTC AAG GTG GAG TCC CCT TC-3′ and 5′-GCG CGC
AAG CTT CTA TTA GGA GTC ATG CCT GGT AGT
GCA TGT TGC-3′. The amplified product was subcloned
into the pSUMO plasmid using the BsaI and HindIII sites
to generate pSUMO-NS5A-domain1+. The QuikChange
Site-Directed Mutagenesis Kit (Stratagene) was used to
mutate four cysteines to serines (C39S, C57S, C59S and
C80S) in pSUMO-NS5A-domain1+ to create pSUMO-5A-
domain1+ 4C-4S.
Purification of NS5A-domain 1+ WT and 4C-4S proteins
The NS5A polypeptides expressed from the pSUMO-based
plasmids were expressed as fusion proteins with SUMO at
the amino terminus. Overexpression of protein in this sys-
tem was performed in the Rosetta (DE3) strain of E. coli
and purified as described previously (30).
RNA sequencing and Actinomycin D mRNA decay assays
To measure the decay of endogenous cellular transcripts in
Huh or Huh-HCV cells, actinomycin D (5 g/ml, Sigma)
was added to the media, and total cellular RNA was col-
lected after 0, 3 and 6 h using the RNeasy kit (Qiagen).
Genome-wide RNA sequencing was performed on tech-
nical duplicate samples to assess mRNA expression lev-
els and mRNA decay rates as described previously (31).
The zero time point was used to determine mRNA ex-
pression levels. Sequencing reads were mapped to the hu-
man genome (hg19) using Bowtie 2.0 with default settings.
Tophat (v2.0.13) and Cufflinks (v2.2.1) were used subse-
quently to generate Fragments Per Kilobase of transcript
per Million (FPKM) mapped reads that were quantified
using custom R scripts. Transcript decay rates were de-
termined following addition of actinomycin D based on a
model of first order decay.
To measure the decay of beta-globin reporter transcripts
in Huh and Huh-HCV cells, the cells were transfected in
a 15 cm dish using 150 l Lipofectamine 2000 (Invitro-
gen) and 15 g of the beta-globin expression plasmids BBB,
BBB-GRE or BBB-ARE as well as 8 g of the pTracerC
GFP expression plasmid. After transfection, each 15 cm
dish of cells was split into three 10 cm dishes. Cells were
treated 48 h later with 5 g/ml of actinomycin D (Sigma),
and total RNA was isolated after 0, 3 or 6 h using the
RNeasy kit (Qiagen), following manufacturer’s recommen-
dations. Residual genomic or plasmid DNA was removed
by digesting 1 g of each sample with 1 unit of DNAse I
(NEB) for 30 min at 37◦C. cDNA was prepared with Super-
script II enzyme (Invitrogen) and oligo dT15 primer from 1
g of total RNA for each time point. Controls without RT
were also prepared from 1 g of total RNA. Quantitative
real time PCR was performed in triplicate for each sample,
and relative concentrations were calculated based on stan-
dard curves for each primer set. The PCR reaction primers
were:
Beta-globin: forward 5′-GAGGGTCTGAATCACCT
GGA-3′ and reverse 5′-GCCAAAATGATGAGACAGC
A-3′.
GFP: forward 5′-TGGAAACATTCTCGGACACA-3′
and reverse 5′-CTTTTCGTTGGGATCTTTCG-3′. These
primers were mixed with the template and the IQ™
SYBR® Green Supermix (Biorad) and amplified SYBR-
green amounts were measured in an iCycler (Biorad) over
time. Beta-globin levels were normalized to GFP levels.
RNA-immunoprecipitation followed by RNA sequencing or
RT-PCR
To identify mRNA targets of NS5A, RNA-IP was per-
formed as described previously (32) on Huh or Huh-HCV
cells using a rabbit polyclonal antibody for NS5A which
was produced at Covance Research Products (Denver, PA)
using the purified recombinant protein NS5A-His as the
antigen (16,18), RNA was purified from the immunopre-
cipitated material using the RNeasy kit (Qiagen) following
manufacturer’s instructions. Genome-wide RNA sequenc-
ing was performed as described previously (31). For each
transcript, we calculated a NS5A-binding parameter called
the fold change in enrichment (FCE) defined as:
FCE = (NS5A IP/input) Huh − HCV
(NS5A IP/input) Huh
where the ratio of the RNA-Seq expression level for each
transcript from the NS5A IP to the level from input RNA
based on duplicate samples for Huh-HCV cells is divided
by the same ratio for Huh cells.
To assess NS5A binding to reporter transcripts, Huh-
HCV (15 cm dish) were transfected with 15 g of BBB or
BBB-GRE reporter plasmids and 8 g of pTracerC plas-
mid in 100–150 l of Lipofectamine 2000. RNA-IP was
performed as described previously (32) using an anti-His
antibody (Santa Cruz Biotech Inc.), anti-NS5A antibody
(16), or anti-PABP antibody (Immuquest). RNA was puri-
fied from the input and immunoprecipitated material using
the RNeasy kit (Qiagen) following manufacturer’s recom-
mendations. cDNA was prepared using Superscript II en-
zyme (Invitrogen), and PCR was performed with the beta-
globin and GFP PCR primers described above.
In vitro RNA–protein binding assay
The fluorescence polarization assay was performed us-
ing a Beacon fluorescence polarization system (Amer-
sham Biosciences) as described previously (18). Recombi-
nant NS5A domain 1+ protein (0–1500 nM) and the 3′-
fluorescein-labeled GRE RNA oligonucleotides or mutant
RNA oligonucleotides shown in Table 1 were gently mixed
in binding reaction buffer (20 mM HEPES, pH 7.5, 5 mM
MgCl2, 10 mM 2-mercaptoethanol, 100 M ZnCl2 and 100
mM NaCl) and incubated briefly at 25◦C. Binding of NS5A
domain 1+ was measured by the change in polarization. All
steps were performed in reduced light. Data were fit to a
hyperbola by using KaleidaGraph software (Synergy Soft-
ware).
Table 1. NS5A affinity (Kd) for binding to RNA oligonucleotides
RNA Sequence Kd (nM)
1 GGCUGAGGCAGG 10 ± 1.5
2 GGGUGGGGGUGG 20 ± 2.7
3 UGUUUGUUUGUCCC 100 ± 10
4 UCUUUCUUUCUCCC 700 ± 200
5 UAUUUAUUUAUCCC 1000 ± 400
6 AAAAAAAAAAAAAAA 1000 ± 150
Tet-off mRNA decay assay
HeLa Tet-off cells (15 cm dish) were transfected with 15
g of the parental BBB reporter plasmid or BBB plasmids
containing 3′ UTR inserts along with 15 g of the NS5A
expression plasmid, mutated NS5A expression plasmids or
mock expression plasmid, and 8 g of the pTracerC GFP
expression plasmid in 100–150 l of Lipofectamine 2000.
After transfection each 15 cm dish was split into five 10 cm
dishes and 48 hours later cells were treated with 300 ng/ml
of doxycycline. After 0, 1.5, 3, 4.5 or 6 h, total RNA was
extracted using the RNeasy kit (Qiagen) following manu-
facturer’s recommendations, and for each sample, 10 g of
RNA was analyzed by northern blot using beta-globin and
GFP probes as described previously (33). To ensure expres-
sion of NS5A or mutated NS5A, protein was extracted from
cells in duplicate plates 48 hours after transfection and ana-
lyzed by western blotting as described previously (34) using
an anti-NS5A antibody (16) and an anti-ERK 1/2 antibody
(Cell signaling).
RESULTS
Host cellular transcripts are stabilized in HCV-expressing
cells
We measured mRNA expression levels and mRNA decay
rates on a genome-wide basis using Actinomycin D mRNA
decay assay in the human hepatoma cell line, Huh 7.5
(Huh), and the same cell line expressing an HCV subge-
nomic replicon (Huh-HCV). Actinomycin D was added to
Huh and Huh-HCV cells to block transcription and total
cellular RNA was collected at 0, 3, and 6 h. This RNA was
analyzed by genome-wide RNA sequencing (RNA-Seq) to
calculate levels of transcript expression and transcript half-
life based on a model of first order decay. We found a total
of 16 714 transcripts were expressed in either Huh or Huh-
HCV cells, 14 894 transcripts were expressed in Huh cells,
15 542 transcripts were expressed in Huh-HCV cells, and
14 359 transcripts were expressed in both. Of these, 6012
transcripts (36%) were up-regulated by >20% and 3903
transcripts (23%) were down-regulated by >20% in Huh-
HCV cells compared to Huh cells. We calculated the half-
life of each transcripts in both Huh and Huh-HCV cells and
found 4945 transcripts (30%) were stabilized (the log of the
decay slope increased by > 50%) and 5131 transcripts (31%)
were destabilized (the log of the decay slope decreased by >
50%) in Huh-HCV cells compared to Huh cells. A master
file containing all the primary gene expression and mRNA
decay data is found in Supplementary Table S1. Overall,
these data suggest that expression of the HCV subgenomic
replicon had a dramatic impact on host gene expression and
mRNA decay.
NS5A binding to host cellular transcripts correlates with
transcript stabilization
Since the HCV NS5A protein is an RNA-binding pro-
tein known to bind to HCV genomic RNA, we hypoth-
esized that NS5A might also bind to host cellular mR-
NAs. To test this hypothesis, we used an anti-NS5A anti-
body to immunoprecipitate (IP) NS5A from cytoplasmic
extracts prepared from Huh-HCV and Huh cells, and we
used RNA-Seq to identify and quantify co-purified host cel-
lular mRNA transcripts. The anti-NS5A antibody used in
this study was previously shown to be specific for NS5A in
Western blot and to specifically immunoprecipitate NS5A
from Huh cells expressing HCV replicon (16,18). For each
transcript, we calculated a NS5A-binding parameter called
the fold change in enrichment (FCE) as defined in the Ma-
terials and Methods. We defined NS5A targets as host tran-
scripts with a FCE > 3 or transcripts present in the NS5A
IP from Huh-HCV cells but absent in the NS5A IP from
Huh cells and identified 960 NS5A target transcripts. A
pathway analysis of these NS5A target transcripts revealed
that 701 transcripts were related to cancer, 294 transcripts
were related to cell growth and proliferation, and 290 tran-
scripts were related to cell death (Ingenuity Pathway As-
sistant software). Supplementary Table S2 shows examples
of NS5A target transcripts, and a complete listing of tar-
get transcripts is found in Supplementary Table S3. Fig-
ure 1 shows examples of functional pathways that contain
NS5A target transcripts involved in apoptosis (Figure 1A)
and cell growth/proliferation (Figure 1B). Thus, we found
that NS5A target transcripts were highly enriched for tran-
scripts encoding regulators of cell growth, cell death and
cancer.
We hypothesized that cytoplasmic binding by NS5A to
host cellular transcripts could alter their mRNA half-life.
To evaluate this, we assessed changes in the mRNA decay
rates of NS5A target transcripts in Huh-HCV cells com-
pared to Huh cells. Of the 960 NS5A target transcripts, 556
(58%) were stabilized in Huh-HCV cells. In contrast, among
8731 transcripts that were not NS5A targets (FCE < or =
1), only 2116 (24%) were found to be stabilized (Figure 2A,
blue bars). This difference was highly significant (P < 2.2 ×
10−16). In addition to enrichment in transcript stabilization,
we also found that NS5A target transcripts were highly en-
riched for up-regulation and stabilization (Figure 2A, red
bars; P < 2.2 × 10−16). For a subset of NS5A target tran-
scripts, we used quantitative RT-PCR to verify that they
were stabilized and upregulated in Huh-HCV cells (Sup-
plementary Table S4). Overall, our data suggest NS5A tar-
gets are highly enriched for transcript stabilization and up-
regulation in Huh-HCV cells.
GRE-containing reporter transcripts are stabilized in Huh-
HCV cells
The HCV NS5A protein functions as an RNA-binding pro-
tein with preference for G- and U-rich sequences (18). We
showed that GU-rich sequences, known as GREs, present
Figure 1. GRE-containing NS5A target transcripts encode regulators of apoptosis (A) and cell growth/proliferation (B). Transcripts depicted in green
are NS5A target transcripts that contain GREs based on a FCE > 3 as defined in the Materials and Methods. These pathway figures were created using
Ingenuity Pathway Assist software (Qiagen Inc).
in the 3′UTR of certain human transcripts target them for
rapid mRNA degradation (22). We found that 118 NS5A
target transcripts contain GRE sequences in their 3′ UTRs,
as defined previously (22,33). We derived a cumulative dis-
tribution of the FCE for NS5A target transcripts that con-
tain a GRE or do not contain a GRE and found greater
binding by NS5A to targets that contained a GRE (P =
0.003, two sample Kolmogorov-Smirnov test, Supplemen-
tary Figure S1). Many other NS5A targets contain 3′ UTR
sequences that are similar to the GRE and are rich in G or U
residues. A de novo motif search was performed using Partek
software to look for conserved sequences in the 3′ UTRs of
NS5A targets based on the RNA sequencing data. The top
12-mer motif, shown in Figure 2B (top sequence), is highly
G rich and resembles a consensus sequence that was previ-
ously found in CELF1 target transcripts (bottom sequence)
(33). Also, a motif resembling a polyU sequence was among
the top 11-mer motifs identified as a consensus sequence
present in NS5A target transcripts (Supplementary Figure
S2). These data are consistent with previous findings that
NS5A could bind to polyU or polyG sequences (18). Since
G and U rich sequences, similar to known NS5A binding
sites, were conserved in the 3′ UTRs of NS5A target tran-
scripts, we hypothesized that NS5A could impact the de-
cay of transcripts containing G and U rich sequences. Our
finding that the consensus NS5A target sequences shown
in Figure 2B (top) has similarity to previously published
GRE sequences (33) suggested a possible relationship be-
tween NS5A binding sites and GREs.
To determine if GU-rich sequences regulate host mRNA
decay in HCV-expressing cells, we transfected Huh or Huh-
HCV cells with beta-globin reporter constructs in which the
JUNB GRE (BBB-GRE) and the IL2 ARE (BBB-ARE)
were inserted into the 3′ UTR. The JUNB GRE and the
IL2 ARE have been previously shown to function as me-
diators of rapid mRNA decay (22,35). The cells were also
co-transfected with a GFP reporter construct to control for
transfection efficiency. Transcription was inhibited by the
addition of actinomycin D, and total RNA was isolated af-
ter 0, 3 and 6 h. Expression of the reporter transcripts was
measured by quantitative RT-PCR and was normalized to
the expression of the GFP transcripts. In this set of exper-
iments, the BBB-GRE transcript decayed rapidly in Huh
cells with a half-life of 80 ± 3 min and was stabilized (P =
0.005) in Huh-HCV cells with a half-life of 392 ± 18 min. In
contrast, the BBB-ARE transcript decayed rapidly in Huh
cells with a half-life of 133 ± 3 min but exhibited only mi-
nor and insignificant stabilization in Huh-HCV cells with
a half-life of 158 ± 4 min (Figure 3). This finding that the
GRE-containing reporter transcript exhibited specific sta-
bilization in replicon-containing cells suggests that a mech-
anism exists for selective recognition of the GRE in HCV
replicon-containing cells.
Binding by the HCV NS5A protein to host cellular transcripts
correlates with transcript stabilization
Because the HCV NS5A protein binds preferentially to
RNA containing GU-rich sequences, we speculated that
NS5A could be responsible for the stabilization of GRE-
containing transcripts in Huh-HCV cells. We performed
RNA-IP assays to determine if we could identify a physical
interaction between NS5A and the GRE in cells that con-
tained the subgenomic HCV replicon. We transfected Huh-
HCV cells with the beta-globin reporter construct (BBB)
Figure 2. NS5A target transcripts are highly enriched for transcript stabi-
lization and up-regulation. (A) The percentage of NS5A target transcripts,
non-NS5A target transcripts and all transcripts that were stabilized (blue
bars) or stabilized and up-regulated (red bars) is shown. ** represents sta-
tistically significant differences (P-value < 10−16, Fisher’s exact test with
R) and *represents statistically significant differences (P-value < 10−11,
Fisher’s extact test, R) in the percentages comparing NS5A target tran-
scripts to Non-NS5A target transcripts or all transcripts. (B) Top: A mo-
tif search was performed to look for conserved consensus sequences in
the 3′ UTRs of NS5A target transcripts. The top 12-mer motif is shown.
The position in the signal (bases) is depicted on the horizontal axis. The
height of each stack of letters on the vertical axis is proportional to the
residue frequency in the given position. Bottom: The motif previously
found in CELF1 target transcripts that resembles the top 12-mer motif
shown above.
or the same reporter carrying the JUNB GRE in its 3′UTR
(BBB-GRE). Two days after transfection, cell lysates were
immunoprecipitated with an anti-His antibody (negative
control), anti-PABP antibody (positive control) or anti-
NS5A antibody, and RNA was isolated from the input ma-
terial (I) and the immunoprecipitation pellet (P). Reverse
transcription PCR was performed on this RNA to evalu-
ate levels of beta-globin transcript and Hypoxanthine Phos-
phoribosyltransferase (HPRT) transcript, which is used as
a housekeeping gene control (Figure 4). In cells transfected
with the BBB-GRE construct, the beta-globin transcript
was present in the NS5A pellet but the HPRT transcript
was not (lane 10), whereas in cells transfected with the BBB
construct, neither the beta-globin nor the HPRT transcripts
were present in the NS5A pellet (lane 4). This result suggests
that NS5A bound specifically in cells only to beta-globin
reporter transcript that contained a GRE. Thus, NS5A was
capable of binding to the GRE in HCV replicon-containing
cells.
We performed in vitro RNA-binding assays to measure
the binding affinity (Kd) of NS5A for the GRE and other
sequences, including RNA sequences derived from the con-
Figure 3. GRE-containing host mRNA transcripts are stabilized in Huh
cells stably expressing an HCV subgenomic replicon (Huh-HCV). Huh or
Huh-HCV cells were transfected with the BBB-GRE or BBB-ARE beta-
globin reporter constructs. Actinomycin D was added to stop transcription
and total cellular RNA was isolated after 0, 3 or 6 h. Specific mRNA levels
were determined by quantitative real time RT-PCR. Beta-globin transcript
levels at each time point were normalized to the transcript levels from a co-
transfected GFP reporter. Transcript levels at the 0 time point were set to
100%, and the percent mRNA remaining was plotted as a function of time.
The error bars indicate the standard error of the mean (SEM) from three
experiments. Transcript half-life and SEM are shown to the right of each
graph.
sensus sequence shown in Figure 2B, top (Table 1). For these
assays, we used a polypeptide that contained the amino ter-
minal domain (domain 1) of NS5A. The structure of do-
main 1 of NS5A has been determined by X-ray crystallog-
raphy (20,21). The protein crystallized as a homodimer, and
the structural integrity of the dimer was dependent on the
tetra-cysteine-coordinated Zn2+ ion (Figure 5A). We puri-
fied a recombinant NS5A polypeptide that contained do-
main 1 plus 36 additional carboxy terminal amino acids;
we refer to this protein as NS5A domain 1+. We also puri-
fied a NS5A derivative that was identical except the 4 cys-
teines in the zinc finger were changed to serines (referred to
as 4C-4S). We used a fluorescence polarization assay (18) to
measure binding of these NS5A polypeptides to fluorescein-
labeled RNA oligonucleotides that contained a minimal
GRE sequence (RNA #3 in Table 1). NS5A domain 1+ was
titrated into a binding mixture containing a 3′-fluorescein
labeled RNA substrate. The median polarization (mP) was
plotted as a function of NS5A domain 1+ concentration,
and the equilibrium dissociation constant was determined
by fitting the data to a hyperbola. NS5A domain 1+ bound
with high affinity to the GRE and this binding depended
on the presence of zinc (Figure 5B). The mutated NS5A
polypeptide (4C-4S), incapable of binding Zn2+ because of
complete disruption of the Zn2+-binding site, failed to bind
to the GRE (Figure 5C). Converting the GRE sequence into
CU- or AU-rich sequences resulted in a 7- to 10-fold reduc-
tion in the observed affinity of NS5A domain 1+ for these
RNAs (Table 1; compare RNA #4 and #5 to #3). Two RNA
sequences derived from the consensus sequence in Figure
2B bound to NS5A domain 1+ with high affinities (Table
1, RNA #1 and #2). Overall, our data support a direct and
Figure 4. NS5A binds to GRE-containing transcripts in cells. Huh7-HCV
cells were transfected with the BBB, or BBB-GRE reporter plasmids. Cell
lysates were immunoprecipitated using specific antibodies against the His-
tag (HIS), NS5A or the poly A binding protein (PABP). RNA isolated
from the input (I) or the pellet fraction (P) was reverse transcribed and
amplified by PCR using beta-globin and HPRT specific primers, and the
RNA was separated by electrophoresis. Water (H2O) was used as a con-
tamination control for the PCR.
specific interaction between NS5A and the GRE in cells and
in vitro.
NS5A directly stabilizes GRE-containing transcripts
Based on our findings that GRE-containing transcripts
were stabilized in Huh-HCV cells and that the HCV NS5A
protein was found to bind to GRE sequences, we hypothe-
sized that binding by NS5A to GRE-containing transcripts
mediates transcript stabilization. To test our hypothesis,
we transfected HeLa cells with the BBB, BBB-GRE, BBB-
mGRE or BBB-ARE beta-globin reporter constructs and
co-transfected them with constructs that expressed wild-
type NS5A (NS5A) or the following NS5A derivatives: 4C-
4S, N or N-4C-4S. A GFP expression construct was also
co-transfected to control for transfection efficiency. Tran-
scription from the tet-responsive promoter was blocked by
the addition of doxycycline, and total RNA was extracted
after 0, 1.5, 3, 4.5 or 6 h. Transcript degradation was mea-
sured over time by northern blot (Figure 6) and the ex-
pression of NS5A or derivatives were monitored by west-
ern blot (Supplementary Figure S3). As expected, the BBB-
reporter alone and the BBB-mGRE reporter were very sta-
ble, whereas the BBB-GRE reporter decayed more rapidly
(half-life = 337 ± 42 minutes). When the NS5A construct
was co-transfected, however, the BBB-GRE transcript was
stabilized (1091 ± 117 min; P = 0.0005). This stabiliz-
ing effect was not observed when the four cysteines that
form the NS5A zinc finger were mutated to serine (4C-4S).
This indicated that a zinc finger-mediated NS5A-GRE in-
teraction was required for stabilization. Published reports
showed that the N-terminal helix of NS5A is required for
tethering the NS5A protein to the viral replication com-
partment of the endoplasmatic reticulum (36–38). Deletion
of the N-terminal helix releases this protein into the cyto-
plasm and decreases viral replication (39). We found that
deletion of the N-terminal 36 amino acids (N) had no ef-
fect on the ability of NS5A to stabilize the GRE-containing
reporter transcript. Deletion of the N-terminal 36 amino
acids and perturbation of the NS5A zinc finger at the same
time (N-4C-4S), however, abrogated the stabilizing activ-
ity of NS5A. In contrast to the GRE-reporter, the ARE re-
porter transcript (BBB-ARE) displayed equal decay in the
presence or absence of NS5A with half-life of 240 ± 15 min-
utes and 228 ± 25 minutes, respectively. This result indicates
that NS5A specifically and selectively mediated the stabi-
lization of GRE-containing, but not ARE-containing tran-
scripts.
DISCUSSION
Introduction of a HCV subgenomic replicon into Huh cells
led to the selective stabilization of host cellular transcripts
through a mechanism that involved binding of NS5A di-
rectly to GU-rich sequences. Not all stabilized transcripts
showed increased abundance. This could be due to other
mechanisms that may affect transcript abundance to main-
tain homeostasis. For NS5A target transcripts we observed
a significantly higher number of transcripts with increased
abundance compared to non-NS5A target transcripts (Fig-
ure 2A). We showed that NS5A binds directly with high
affinity to GRE sequences, and may bind to other G or
U-rich sequences that were conserved in the 3′ UTRs of
NS5A target transcripts. Our finding in HeLa cells that ex-
ogenous expression of NS5A specifically stabilizes GRE-
containing transcripts clearly demonstrates that NS5A pos-
sesses mRNA-stabilizing activity (Figure 6). This function
of NS5A enables HCV to control host cellular gene expres-
sion.
The results presented here support previous work sug-
gesting that NS5A functions as an RNA-binding protein.
NS5A interacts with HCV genomic RNA (18,19) and was
shown to bind to polyU or polyG sequences (18). Our re-
sults indicate that a G-rich consensus sequence was present
in the 3′ UTRs of NS5A target transcripts (Figure 2B).
This sequence resembles the G-rich consensus sequence pre-
viously found in CELF1 target transcripts (33). In addi-
tion, NS5A is also reported to bind to poly(U/UC) se-
quence in the 3′UTR of HCV RNA and downregulates viral
RNA translation (40). We found similar poly(U/UC)-rich
sequences were present within the 3′UTR of NS5A target
transcripts (Supplementary Figure S2). It is reported that
GRE sequences are very common in the genome. Although
GREs were found in NS5A target transcripts, they were not
enriched. Our data shows that the GRE can function as a
site for NS5A, but not all GRE-containing transcripts are
NS5A targets. This may be due to secondary structures, ge-
nomic context, or availability for binding sites.
Our results confirm the RNA-binding activity of NS5A
and suggest that the GRE sequence, UGUUUGUU-
UGU (22), is a binding target for NS5A. We showed
by RNA immunoprecipitation that an anti-NS5A anti-
body specifically co-immunoprecipitated GRE-containing
reporter transcripts, but not reporter transcripts that lacked
a GRE (Figure 4). These results suggest that the GRE func-
tions as a target of NS5A within cells. Our in vitro binding
experiments showed that NS5A binding to the GRE was de-
pendent upon the C4 zinc finger motif in domain 1 since no
GRE-binding activity was observed when the four cysteines
were mutated to serines (Figure 5C). Also, no binding pre-
sented in the absence of zinc (Figure 5B), suggesting that co-
ordination of zinc is critical for binding. Crystal structures
of domain 1 dimers revealed the presence of a cleft near
the zinc-coordinating sites that may facilitate RNA binding
Figure 5. Recombinant NS5A binds to GRE RNA in a manner that is dependent on an intact zinc-binding site and the presence of zinc. (A) The upper
panel shows a ribbon diagram of dimeric NS5A domain 1 that was prepared by using reference number 1ZH1 from the Protein Data Bank. One subunit
is colored red and the other is colored green. The lower panel zooms in on the zinc-binding site of each subunit. Four conserved cysteines are required
for zinc binding. (B) The NS5A domain 1+ polypeptide was titrated into a binding reaction buffer (20 mM HEPES pH 7.5, 5 mM MgCl2, 10 mM 2-
mercaptoethanol, 100 mM NaCl) in the absence (-Zn2+) or presence (+Zn2+) of 100 M ZnCl2 and incubated briefly at 25◦C in a final volume of 100 l.
Binding of NS5A was measured by the change in polarization (mP). The change in fluorescence polarization was plotted as a function of NS5A domain 1+
concentration and fit to a hyperbola by using KaleidaGraph (Synergy Software). (C) Experiments were performed as described in panel B in the presence
of zinc using the NS5A domain 1+ polypeptide (WT) or the derivative whose zinc-binding site was inactivated by converting the four cysteine residues to
serine residues (4C-4S).
(20,21) (Figure 5A). Collectively, our findings suggest that
the zinc finger motif contributes to the functional form of
NS5A that enables specific interaction of NS5A with GRE
RNA.
We previously showed that the GRE mediates rapid
mRNA decay by binding to CELF1 (22), which appears to
recruit components of the cellular mRNA decay machinery
such as poly A ribonuclease (25). In the presence of NS5A,
the rapid decay of the GRE-containing reporter was com-
pletely abolished (Figure 6), suggesting that NS5A might
potentially antagonize the activity of CELF1. CELF1 and
NS5A appear to have overlapping binding specificities since
they both bind directly to G-rich sequences, including the
GRE, but a subset of NS5A target transcripts might not
be targets of CELF1. These proteins have different mech-
anisms for RNA binding. NS5A binding involves zinc fin-
ger domains, whereas CELF1 binding involves RNA recog-
nition motifs, yet their binding target sites appear to over-
lap, at least in the case of GRE sequences. Further work is
needed to better define the sites for binding by these pro-
teins to host transcripts.
Viruses have developed mechanisms to manipulate host
gene expression at posttranscriptional levels in order to sub-
vert antiviral defense mechanisms and to create an environ-
ment in the virus-infected cell that will prevent cell death
and allow viral replication. Kaposi’s sarcoma virus (1) and
Herpes simplex virus (2) produce nucleases that mediate
host mRNA decay. Herpes simplex virus also produces the
ICP27 protein which mediates the stabilization of AU-rich
element-containing host transcript (3) and Epstein-Barr
virus infection leads to the stabilization of mRNAs through
the activation of the stress activated protein kinase p38 (41).
Several studies found differential host gene expression in
cell cultures infected with HCV using high-throughput ap-
proaches and screens (42–46), but the mechanism of how
the host gene expression is regulated by the virus is not
well understood. Luna et al. proposed that microRNA-122
sequestration by HCV RNA may lead to stabilization of
miR-122 targets, facilitating the oncogenesis of HCV (47).
Moon et al. demonstrated another mechanism that HCV
utilizes to affect host mRNA decay. They found the 5′UTR
of HCV genomic RNA can stall and suppress the cellu-
lar 5′-3′ exoribonuclease Xrn1, leading to global stabiliza-
tion of cellular transcripts (48). The mechanism by which
HCV stabilizes GRE-containing transcripts, described in
this report, depends on the direct interaction between the
NS5A protein and GU-rich sequences within host cellu-
lar mRNA. Through this mechanism, HCV blocks the host
mRNA degradation machinery and selectively stabilizes a
set of GU-rich transcripts that may be necessary for estab-
lishment or maintenance of chronic HCV infection.
Many of the short-lived GRE-containing transcripts in
mammalian cells encode proto-oncogenes and other impor-
tant regulators of cell growth and apoptosis, constituting
a network of coordinately regulated transcripts (23). These
GRE-containing transcripts include proto-oncogene tran-
Figure 6. Exogenously expressed NS5A stabilizes GRE-containing reporter genes. (A) HeLa tet-off cells were transfected with BBB, BBB-GRE, BBB-ARE
or BBB-mGRE reporter plasmids as well as a plasmid that express NS5A, NS5A-4C-4S, N-NS5A, N-NS5A-4C-4S or a mock control plasmid. A GFP
expression plasmid was included in each to control for transfection efficiency. Transcription from the tet-responsive promoter was stopped with 300 ng
of doxycycline and RNA harvested after 0, 1.5, 3, 4.5 or 6 h was analyzed by northern blotting using GFP and beta-globin probes. (B) The experiment
shown in (A) was performed three times, and the northern blot signals were quantified by a Storm 820 phosphorimager (Amersham Biosciences). For each
time point, the intensity of the beta-globin reporter was normalized to the intensity of the GFP band, and the band intensity at the 0 time point was set
to 100%. The percent of mRNA remaining was plotted over time. The error bars indicate the standard error of the mean (SEM) from three experiments.
The calculated transcript half-life and SEM are shown to the right of each graph.
scripts such as JUN, JUNB, JUND, and ETS2, transcripts
encoding regulators of apoptosis such as BCL10, BAG,
MAP3K5, and TNFRSF1, and transcripts encoding other
regulators of cell growth including EIF4EBP2, EIF4G3,
SMAD7 and HOXC10. After infection with HCV, NS5A-
mediated stabilization and overexpression of these GRE-
containing transcripts would be predicted to promote cell
growth and prevent cell death in order to allow a chronic
infection to be established. It is possible that new drugs that
block the NS5A interaction with the GRE could be devel-
oped that would prevent establishment of chronic HCV in-
fections and inhibit the maintenance or propagation of in-
fection. Indeed, drugs like ledipasvir that target NS5A but
whose mechanism of action remain unclear (49) might func-
tion by perturbing the ability of NS5A to bind GREs or
similar G or U rich sequences and modulate host gene ex-
pression.
Infection with HCV increases the risk for hepatocellu-
lar carcinoma development as well as certain lymphomas
(50,51). The onset of the tumors, however, occurs many
years after HCV infection, suggesting that multiple events
are required to transform hepatic cells to become malig-
nant (52). Progression of liver fibrosis to cirrhosis in HCV-
infected patients will generate a local milieu that predis-
poses to liver cancer. In this environment, changes occur
to the hepatic parenchyma, with hepatocyte injury, which
contributes to sequential genetic hits that culminate in ma-
lignant transformation (53). However, the mechanisms in-
volved in this process are largely unknown. Moreover, mul-
tiple studies have showed a direct role for HCV in hep-
atic carcinogenesis and transgenic mice expressing the HCV
polyprotein can develop liver cancer in the absence of in-
flammation, hepatic cirrhosis or immune recognition of the
transgene (13,54,55). The stabilization and overexpression
of GRE-containing transcripts including proto-oncogene
transcripts and transcripts encoding regulators of apoptosis
may contribute to the development of cancer by promoting
cell growth and preventing the death of genetically damaged
cells. Later events that finally lead to uncontrolled growth of
these cells might destroy the fail-safe mechanisms that are
initially able to cope with the increased stability of these im-
portant messages.
In conclusion, our findings describe a novel role of NS5A
in stabilizing host GRE-containing transcripts, providing
new insights into HCV pathogenesis and carcinogenesis
that may lead to new treatments to prevent HCV infection
and understand the progression to liver cancer.
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